Putting p53 in context

Integrative Analysis of Complex Cancer Genomics and Clinical Profiles Using the cBioPortal

Gao, J., Aksoy, B. A., Dogrusoz, U., Dresdner, G., Gross, B., Sumer, S. O., Sun, Y., Jacobsen, A., Sinha, R., Larsson, E., et al. (2013) · Science Signaling · doi:10.1126/scisignal.2004088 · Cited by 15,160 · see citing works

Signatures of mutational processes in human cancer

Initiative, A. P. C. G., Alexandrov, L. B., ICGC Breast Cancer Consortium, ICGC MMML-Seq Consortium, PedBrain, I., Nik-Zainal, S., Wedge, D. C., Aparicio, S. A. J. R., Behjati, S., Biankin, A. V., et al. (2013) · Nature · doi:10.1038/nature12477 · Cited by 9,660 · see citing works

WAF1, a potential mediator of p53 tumor suppression

El-Deiry, W. S., Tokino, T., Velculescu, V. E., Levy, D. B., Parsons, R., Trent, J. M., Lin, D., Mercer, W. E., Kinzler, K. W., & Vogelstein, B. (1993) · Cell · doi:10.1016/0092-8674(93)90500-p · Cited by 8,321 · see citing works

The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases.

Wade Harper, J. (1993) · Cell · doi:10.1016/0092-8674(93)90499-g · Cited by 5,651 · see citing works

Oncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK4a

Serrano, M., Lin, A. W., McCurrach, M. E., Beach, D., & Lowe, S. W. (1997) · Cell · doi:10.1016/s0092-8674(00)81902-9 · Cited by 5,178 · see citing works

p53, guardian of the genome

Lane, D. P. (1992) · Nature · doi:10.1038/358015a0 · Cited by 5,138 · see citing works

In Vivo Activation of the p53 Pathway by Small-Molecule Antagonists of MDM2

Vassilev, L. T., Vu, B. T., Graves, B., Carvajal, D., Podlaski, F., Filipovic, Z., Kong, N., Kammlott, U., Lukacs, C., Klein, C., et al. (2004) · Science · doi:10.1126/science.1092472 · Cited by 4,661 · see citing works

Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours

Donehower, L. A., Harvey, M., Slagle, B. L., McArthur, M. J., Montgomery, C. A., Butel, J. S., & Bradley, A. (1992) · Nature · doi:10.1038/356215a0 · Cited by 4,649 · see citing works

Mdm2 promotes the rapid degradation of p53

Haupt, Y., Maya, R., Kazaz, A., & Oren, M. (1997) · Nature · doi:10.1038/387296a0 · Cited by 4,506 · see citing works

Germ Line p53 Mutations in a Familial Syndrome of Breast Cancer, Sarcomas, and Other Neoplasms

Malkin, D., Li, F. P., Strong, L. C., Fraumeni, J. F., Nelson, C. E., Kim, D. H., Kassel, J., Gryka, M. A., Bischoff, F. Z., Tainsky, M. A., et al. (1990) · Science · doi:10.1126/science.1978757 · Cited by 3,765 · see citing works

Participation of p53 protein in the cellular response to DNA damage.

Kastan, M. B., Onyekwere, O. C., Sidransky, D., Vogelstein, B., & Craig, R. W. (1991) · PubMed · Cited by 3,761 · see citing works

Inactivation of the ferroptosis regulator Gpx4 triggers acute renal failure in mice

Friedmann Angeli, J. P., Schneider, M., Proneth, B., Tyurina, Y. Y., Tyurin, V. A., Hammond, V. J., Herbach, N., Aichler, M., Walch, A., Eggenhofer, E., et al. (2014) · Nature Cell Biology · doi:10.1038/ncb3064 · Cited by 3,732 · see citing works

Comprehensive molecular characterization of clear cell renal cell carcinoma

The Cancer Genome Atlas Research Network (2013) · Nature · doi:10.1038/nature12222 · Cited by 3,485 · see citing works

Ferroptosis as a p53-mediated activity during tumour suppression

Jiang, L., Kon, N., Li, T., Wang, S.-J., Su, T., Hibshoosh, H., Baer, R., & Gu, W. (2015) · Nature · doi:10.1038/nature14344 · Cited by 3,398 · see citing works

Regulation of p53 stability by Mdm2

Kubbutat, M. H. G., Jones, S. N., & Vousden, K. H. (1997) · Nature · doi:10.1038/387299a0 · Cited by 3,312 · see citing works

p53 is required for radiation-induced apoptosis in mouse thymocytes

Lowe, S. W., Schmitt, E. M., Smith, S. W., Osborne, B. A., & Jacks, T. (1993) · Nature · doi:10.1038/362847a0 · Cited by 2,864 · see citing works

Clonal heterogeneity and tumor evolution: past, present, and the future

McGranahan, N., & Swanton, C. (2017) · Cell · doi:10.1016/j.cell.2017.01.018 · Cited by 2,840 · see citing works

Senescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas

Xue, W., Zender, L., Miething, C., Dickins, R. A., Hernando, E., Krizhanovsky, V., Cordon-Cardo, C., & Lowe, S. W. (2007) · Nature · doi:10.1038/nature05529 · Cited by 2,473 · see citing works

T antigen is bound to a host protein in SY40-transformed cells

Lane, D. P., & Crawford, L. V. (1979) · Nature · doi:10.1038/278261a0 · Cited by 2,443 · see citing works

Thymocyte apoptosis induced by p53-dependent and independent pathways

Clarke, A. R., Purdie, C. A., Harrison, D. J., Morris, R. G., Bird, C. C., Hooper, M. L., & Wyllie, A. H. (1993) · Nature · doi:10.1038/362849a0 · Cited by 2,271 · see citing works

TP53 mutations in human cancers: origins, consequences, and clinical use.

Olivier, M., Hollstein, M., & Hainaut, P. (2010) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a001008 · Cited by 2,199 · see citing works

Tumor suppressor p53 is a regulator of bcl-2 and bax gene expression in vitro and in vivo.

Miyashita, T., Krajewski, S., Krajewska, M., Wang, H., Lin, H., Liebermann, D. A., Hoffman‐Liebermann, B., & Reed, J. C. (1994) · PubMed · Cited by 2,143 · see citing works

DNA damage-induced phosphorylation of p53 alleviates inhibition by MDM2

Shieh, S.-Y., Ikeda, M., Taya, Y., & Prives, C. (1997) · Cell · doi:10.1016/s0092-8674(00)80416-x · Cited by 2,100 · see citing works

Wild-type p53 induces apoptosis of myeloid leukaemic cells that is inhibited by interleukin-6

Yonish-Rouach, E., Resnftzky, D., Lotem, J., Sachs, L., Kimchi, A., & Oren, M. (1991) · Nature · doi:10.1038/352345a0 · Cited by 2,079 · see citing works

Senescence of activated stellate cells limits liver fibrosis

Krizhanovsky, V., Yon, M., Dickins, R. A., Hearn, S., Simon, J., Miething, C., Yee, H., Zender, L., & Lowe, S. W. (2008) · Cell · doi:10.1016/j.cell.2008.06.049 · Cited by 2,029 · see citing works

Senescence of Activated Stellate Cells Limits Liver Fibrosis

Krizhanovsky, V., Yon, M., Dickins, R. A., Hearn, S., Simon, J., Miething, C., Yee, H., Zender, L., & Lowe, S. W. (2008) · Cell · doi:10.1016/j.cell.2008.09.015 · Cited by 2,027

The p53 proto-oncogene can act as a suppressor of transformation

Finlay, C. A., Hinds, P. W., & Levine, A. J. (1989) · Cell · doi:10.1016/0092-8674(89)90045-7 · Cited by 1,987 · see citing works

Clonal hematopoiesis of indeterminate potential and its distinction from myelodysplastic syndromes

Steensma, D. P., Bejar, R., Jaiswal, S., Lindsley, R. C., Sekeres, M. A., Hasserjian, R. P., & Ebert, B. L. (2015) · Blood · doi:10.1182/blood-2015-03-631747 · Cited by 1,971 · see citing works

Oncoprotein MDM2 is a ubiquitin ligase E3 for tumor suppressor p53

Honda, R., Tanaka, H., & Yasuda, H. (1997) · FEBS Letters · doi:10.1016/s0014-5793(97)01480-4 · Cited by 1,951 · see citing works

Ferroptosis is an autophagic cell death process

Gao, M., Monian, P., Pan, Q., Zhang, W., Xiang, J., & Jiang, X. (2016) · Cell Research · doi:10.1038/cr.2016.95 · Cited by 1,899 · see citing works

Age-related mutations associated with clonal hematopoietic expansion and malignancies

Xie, M., Lu, C., Wang, J., McLellan, M. D., Johnson, K. J., Wendl, M. C., McMichael, J. F., Schmidt, H. K., Yellapantula, V., Miller, C. A., et al. (2014) · Nature Medicine · doi:10.1038/nm.3733 · Cited by 1,874 · see citing works

Restoration of p53 function leads to tumour regression in vivo

Ventura, A., Kirsch, D. G., McLaughlin, M. E., Tuveson, D. A., Grimm, J., Lintault, L., Newman, J., Reczek, E. E., Weissleder, R., & Jacks, T. (2007) · Nature · doi:10.1038/nature05541 · Cited by 1,820 · see citing works

Characterization of a 54K Dalton cellular SV40 tumor antigen present in SV40-transformed cells and uninfected embryonal carcinoma cells

Linzer, D. I. H., & Levine, A. J. (1979) · Cell · doi:10.1016/0092-8674(79)90293-9 · Cited by 1,814 · see citing works

ARF promotes MDM2 degradation and stabilizes p53: ARF-INK4a locus deletion impairs both the Rb and p53 tumor suppression pathways

Zhang, Y., Xiong, Y., & Yarbrough, W. G. (1998) · Cell · doi:10.1016/s0092-8674(00)81401-4 · Cited by 1,626 · see citing works

Mutant p53 in Cancer: New Functions and Therapeutic Opportunities

Muller, P. A. J., & Vousden, K. H. (2014) · Cancer Cell · doi:10.1016/j.ccr.2014.01.021 · Cited by 1,545 · see citing works

The Ink4a tumor suppressor gene product, p19Arf, interacts with MDM2 and neutralizes MDM2’s inhibition of p53

Pomerantz, J., Schreiber-Agus, N., Liégeois, N. J., Silverman, A., Alland, L., Chin, L., Potes, J., Chen, K., Orlow, I., Lee, H.-W., et al. (1998) · Cell · doi:10.1016/s0092-8674(00)81400-2 · Cited by 1,521 · see citing works

Alternative reading frames of the INK4a tumor suppressor gene encode two unrelated proteins capable of inducing cell cycle arrest

Ouelle, D. E., Zindy, F., Ashmun, R. A., & Sherr, C. J. (1995) · Cell · doi:10.1016/0092-8674(95)90214-7 · Cited by 1,485 · see citing works

Emerging landscape of oncogenic signatures across human cancers

Ciriello, G., Miller, M. L., Aksoy, B. A., Şenbabaoğlu, Y., Schultz, N. D., & Sander, C. (2013) · Nature Genetics · doi:10.1038/ng.2762 · Cited by 1,382 · see citing works

Altered cell cycle arrest and gene amplification potential accompany loss of wild-type p53

Livingstone, L. R., White, A., Sprouse, J., Livanos, E., Jacks, T., & Tlsty, T. D. (1992) · Cell · doi:10.1016/0092-8674(92)90243-6 · Cited by 1,333 · see citing works

Mutant p53 gain of function in two mouse models of Li-Fraumeni syndrome

Olive, K. P., Tuveson, D. A., Ruhe, Z. C., Yin, B., Willis, N. A., Bronson, R. T., Crowley, D., & Jacks, T. (2004) · Cell · doi:10.1016/j.cell.2004.11.004 · Cited by 1,308 · see citing works

Mutant p53: one name, many proteinsPreprint

Freed-Pastor, W. A., & Prives, C. L. (2012) · Genes & Development · doi:10.1101/gad.190678.112 · Cited by 1,246 · see citing works

Mutational signatures associated with tobacco smoking in human cancer

Alexandrov, L. B., Ju, Y. S., Haase, K., Van Loo, P., Martincorena, I., Nik-Zainal, S., Totoki, Y., Fujimoto, A., Nakagawa, H., Shibata, T., et al. (2016) · Science · doi:10.1126/science.aag0299 · Cited by 1,100 · see citing works

Wild-type p53 restores cell cycle control and inhibits gene amplification in cells with mutant p53 alleles

Yin, Y., Tainsky, M. A., Bischoff, F. Z., Strong, L. C., & Wahl, G. M. (1992) · Cell · doi:10.1016/0092-8674(92)90244-7 · Cited by 1,089 · see citing works

FOXOs: signalling integrators for homeostasis maintenance

Eijkelenboom, A., & Burgering, B. M. T. (2013) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3507 · Cited by 1,081 · see citing works

P53 in survival, death and metabolic health: a lifeguard with a licence to kill.

Kruiswijk, F., Labuschagne, C. F., & Vousden, K. H. (2015) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm4007 · Cited by 1,080 · see citing works

Autophagy mediates the mitotic senescence transition

Young, A. R. J., Narita, M., Ferreira, M., Kirschner, K., Sadaie, M., Darot, J. F. J., Tavaré, S., Arakawa, S., Shimizu, S., Watt, F. M., et al. (2009) · Genes & Development · doi:10.1101/gad.519709 · Cited by 1,078 · see citing works

p53 gene mutations occur in combination with 17p allelic deletions as late events in colorectal tumorigenesis.

Baker, S. J., Preisinger, A. C., Jessup, J. M., Paraskeva, C., Markowitz, S. D., Willson, J. K. V., Hamilton, S. R., & Vogelstein, B. (1990) · PubMed · Cited by 1,065 · see citing works

SOX2 promotes lineage plasticity and antiandrogen resistance in TP53 - and RB1 -deficient prostate cancer

Mu, P., Zhang, Z., Benelli, M., Karthaus, W. R., Hoover, E., Chen, C.-C., Wongvipat, J., Ku, S., Gao, D., Cao, Z., et al. (2017) · Science · doi:10.1126/science.aah4307 · Cited by 1,063 · see citing works

Census and evaluation of p53 target genes

Fischer, M. (2017) · Oncogene · doi:10.1038/onc.2016.502 · Cited by 971 · see citing works

Role of TP53 mutations in the origin and evolution of therapy-related acute myeloid leukaemia

Wong, T. N., Ramsingh, G., Young, A. L., Miller, C. A., Touma, W., Welch, J. S., Lamprecht, T. L., Shen, D., Hundal, J., Fulton, R. S., et al. (2015) · Nature · doi:10.1038/nature13968 · Cited by 892 · see citing works

Genome sequencing of pediatric medulloblastoma links catastrophic DNA rearrangements with TP53 mutations

Rausch, T., Jones, D. T. W., Zapatka, M., Stütz, A. M., Zichner, T., Weischenfeldt, J., Jäger, N., Remke, M., Shih, D., Northcott, P. A., et al. (2012) · Cell · doi:10.1016/j.cell.2011.12.013 · Cited by 865 · see citing works

Mutant p53 disrupts mammary tissue architecture via the mevalonate pathway

Freed-Pastor, W. A., Mizuno, H., Zhao, X., Langerød, A., Moon, S.-H., Rodriguez-Barrueco, R., Barsotti, A., Chicas, A., Li, W., Polotskaia, A., et al. (2012) · Cell · doi:10.1016/j.cell.2011.12.017 · Cited by 865 · see citing works

p53 in the DNA–Damage–Repair Process

Williams, A. B., & Schumacher, B. (2016) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a026070 · Cited by 835 · see citing works

<i>TP53</i> and Decitabine in Acute Myeloid Leukemia and Myelodysplastic Syndromes

Welch, J. S., Petti, A. A., Miller, C. A., Fronick, C. C., O’Laughlin, M., Fulton, R. S., Wilson, R. K., Baty, J. D., Duncavage, E. J., Tandon, B., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1605949 · Cited by 796 · see citing works

Non-Cell-Autonomous Tumor Suppression by p53

Lujambio, A., Akkari, L., Simon, J., Grace, D., Tschaharganeh, D. F., Bolden, J. E., Zhao, Z., Thapar, V., Joyce, J. A., Krizhanovsky, V., et al. (2013) · Cell · doi:10.1016/j.cell.2013.03.020 · Cited by 766 · see citing works

Evidence for APOBEC3B mutagenesis in multiple human cancers

Burns, M. B., Temiz, N. A., & Harris, R. S. (2013) · Nature Genetics · doi:10.1038/ng.2701 · Cited by 763 · see citing works

A role for both RB and p53 in the regulation of human cellular senescence*1

SHAY, J. (1991) · Experimental Cell Research · doi:10.1016/0014-4827(91)90453-2 · Cited by 757 · see citing works

Detection of a transformation-related antigen in chemically induced sarcomas and other transformed cells of the mouse.

DeLeo, A. B., Jay, G. D., Appella, E., DuBois, G. C., Law, L. W., & Old, L. J. (1979) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.76.5.2420 · Cited by 721 · see citing works

Loss of genomic methylation causes p53-dependent apoptosis and epigenetic deregulation

Jackson-Grusby, L., Beard, C., Possemato, R., Tudor, M., Fambrough, D., Csankovszki, G., Dausman, J., Lee, P., Wilson, C., Lander, E., et al. (2001) · Nature Genetics · doi:10.1038/83730 · Cited by 694 · see citing works

PDL1 Regulation by p53 via miR-34

Cortez, M. A., Ivan, C., Valdecanas, D., Wang, X., Peltier, H. J., Ye, Y., Araujo, L., Carbone, D. P., Shilo, K., Giri, D. K., et al. (2016) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djv303 · Cited by 683 · see citing works

Chromothripsis and Kataegis Induced by Telomere Crisis

Maciejowski, J., Li, Y., Bosco, N., Campbell, P. J., & de Lange, T. (2015) · Cell · doi:10.1016/j.cell.2015.11.054 · Cited by 675 · see citing works

The senescence-associated secretory phenotype induces cellular plasticity and tissue regeneration.

Ritschka, B., Storer, M., Mas, A., Heinzmann, F., Ortells, M. C., Morton, J. P., Sansom, O. J., Zender, L., & Keyes, W. M. (2017) · Genes &amp; Development · doi:10.1101/gad.290635.116 · Cited by 650 · see citing works

Modeling the Therapeutic Efficacy of p53 Restoration in Tumors

Martins, C. P., Brown-Swigart, L., & Evan, G. I. (2006) · Cell · doi:10.1016/j.cell.2006.12.007 · Cited by 600 · see citing works

Dedifferentiation of Neurons and Astrocytes by Oncogenes Can Induce Gliomas in Mice

Friedmann‐Morvinski, D., Bushong, E. A., Ke, E., Soda, Y., Marumoto, T., Singer, O., Ellisman, M. H., & Verma, I. M. (2012) · Science · doi:10.1126/science.1226929 · Cited by 566 · see citing works

p53 Regulates Hematopoietic Stem Cell Quiescence

Liu, Y., Elf, S. E., Miyata, Y., Sashida, G., Liu, Y., Huang, G., Di Giandomenico, S., Lee, J. M., Deblasio, A., Menendez, S., et al. (2009) · Cell Stem Cell · doi:10.1016/j.stem.2008.11.006 · Cited by 547 · see citing works

Aberrant Overexpression of Satellite Repeats in Pancreatic and Other Epithelial Cancers

Ting, D. T., Lipson, D., Paul, S., Brannigan, B. W., Akhavanfard, S., Coffman, E. J., Contino, G., Deshpande, V., Iafrate, A. J., Letovsky, S., et al. (2011) · Science · doi:10.1126/science.1200801 · Cited by 540 · see citing works

Distinct p53 Transcriptional Programs Dictate Acute DNA-Damage Responses and Tumor Suppression

Brady, C. A., Jiang, D., Mello, S. S., Johnson, T. M., Jarvis, L. A., Kozak, M. M., Broz, D. K., Basak, S., Park, E. J., McLaughlin, M. E., et al. (2011) · Cell · doi:10.1016/j.cell.2011.03.035 · Cited by 533 · see citing works

Human pluripotent stem cells recurrently acquire and expand dominant negative P53 mutations

Merkle, F. T., Ghosh, S., Kamitaki, N., Mitchell, J., Avior, Y., Mello, C., Kashin, S., Mekhoubad, S., Ilic, D., Charlton, M., et al. (2017) · Nature · doi:10.1038/nature22312 · Cited by 506 · see citing works

Transcriptional regulation by p53: one protein, many possibilities

Laptenko, O., & Prives, C. L. (2006) · Cell Death and Differentiation · doi:10.1038/sj.cdd.4401916 · Cited by 500 · see citing works

Gain-of-function p53 mutants co-opt chromatin pathways to drive cancer growth

Zhu, J., Sammons, M. A., Donahue, G., Dou, Z., Vedadi, M., Getlik, M., Barsyte-Lovejoy, D., Al-awar, R., Katona, B. W., Shilatifard, A., et al. (2015) · Nature · doi:10.1038/nature15251 · Cited by 493 · see citing works

Characterization of the p53-Dependent Postmitotic Checkpoint following Spindle Disruption

Lanni, J. S., & Jacks, T. (1998) · Molecular and Cellular Biology · doi:10.1128/mcb.18.2.1055 · Cited by 493 · see citing works

Reciprocal regulation of p53 and malic enzymes modulates metabolism and senescence

Jiang, P., Du, W., Mancuso, A., Wellen, K. E., & Yang, X. (2013) · Nature · doi:10.1038/nature11776 · Cited by 491 · see citing works

Potential Mechanisms for Cancer Resistance in Elephants and Comparative Cellular Response to DNA Damage in Humans

Abegglen, L. M., Caulin, A. F., Chan, A., Lee, K., Robinson, R., Campbell, M. S., Kiso, W. K., Schmitt, D. L., Waddell, P. J., Bhaskara, S., et al. (2015) · JAMA · doi:10.1001/jama.2015.13134 · Cited by 485 · see citing works

Mutant p53 Drives Pancreatic Cancer Metastasis through Cell-Autonomous PDGF Receptor β Signaling

Weissmueller, S., Manchado, E., Saborowski, M., Morris, J. P., Wagenblast, E., Davis, C. A., Moon, S.-H., Pfister, N. T., Tschaharganeh, D. F., Kitzing, T., et al. (2014) · Cell · doi:10.1016/j.cell.2014.01.066 · Cited by 466 · see citing works

Detection of antibodies against the cellular protein p53 in sera from patients with breast cancer

Crawford, L. V., Pim, D. C., & Bulbrook, R. D. (1982) · International Journal of Cancer · doi:10.1002/ijc.2910300404 · Cited by 454 · see citing works

Tolerance of Whole-Genome Doubling Propagates Chromosomal Instability and Accelerates Cancer Genome Evolution

Dewhurst, S. M., McGranahan, N., Burrell, R. A., Rowan, A., Gronroos, E. C., Endesfelder, D., Joshi, T., Mouradov, D., Gibbs, P., Ward, R. L., et al. (2014) · Cancer Discovery · doi:10.1158/2159-8290.cd-13-0285 · Cited by 450 · see citing works

Tumour-associated mutant p53 drives the Warburg effect

Zhang, C., Liu, J., Liang, Y., Wu, R., Zhao, Y., Hong, X., Lin, M., Yu, H., Liu, L., Levine, A. J., et al. (2013) · Nature Communications · doi:10.1038/ncomms3935 · Cited by 434 · see citing works

Extensive transduction of nonrepetitive DNA mediated by L1 retrotransposition in cancer genomes

Tubio, J. M. C., Li, Y., Ju, Y. S., Martincorena, I., Cooke, S. L., Tojo, M., Gundem, G., Pipinikas, C. P., Zamora, J., Raine, K., et al. (2014) · Science · doi:10.1126/science.1251343 · Cited by 412 · see citing works

Targeted rescue of a destabilized mutant of p53 by an in silico screened drug

Boeckler, F. M., Joerger, A. C., Jaggi, G., Rutherford, T. J., Veprintsev, D. B., & Fersht, A. R. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0805326105 · Cited by 389 · see citing works

Cytokinesis Failure Triggers Hippo Tumor Suppressor Pathway Activation

Ganem, N. J., Cornils, H., Chiu, S.-Y., O’Rourke, K. P., Arnaud, J., Yimlamai, D., Théry, M., Camargo, F. D., & Pellman, D. S. (2014) · Cell · doi:10.1016/j.cell.2014.06.029 · Cited by 375 · see citing works

Improving survival by exploiting tumour dependence on stabilized mutant p53 for treatment

Alexandrova, E. M., Yallowitz, A. R., Li, D., Xu, S., Schulz‐Heddergott, R., Proia, D. A., Lozano, G., Dobbelstein, M., & Moll, U. M. (2015) · Nature · doi:10.1038/nature14430 · Cited by 354 · see citing works

An epi-allelic series of p53 hypomorphs created by stable RNAi produces distinct tumor phenotypes in vivo

Hemann, M. T., Fridman, J. S., Zilfou, J. T., Hernando, E., Paddison, P. J., Cordon‐Cardo, C., Hannon, G. J., & Lowe, S. W. (2003) · Nature Genetics · doi:10.1038/ng1091 · Cited by 354 · see citing works

Results of the Phase I trial of RG7112, a small-molecule MDM2 antagonist in leukemia

Andreeff, M., Kelly, K. R., Yee, K., Assouline, S., Strair, R., Popplewell, L., Bowen, D., Martinelli, G., Drummond, M. W., Vyas, P., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-0481 · Cited by 352 · see citing works

Identification of Aneuploidy-Selective Antiproliferation Compounds

Tang, Y., Williams, B. R., Siegel, J. J., & Amon, A. (2011) · Cell · doi:10.1016/j.cell.2011.01.017 · Cited by 348 · see citing works

p53-Mediated Hematopoietic Stem and Progenitor Cell Competition

Bondar, T., & Medzhitov, R. (2010) · Cell Stem Cell · doi:10.1016/j.stem.2010.03.002 · Cited by 342 · see citing works

TP53 copy number expansion is associated with the evolution of increased body size and an enhanced DNA damage response in elephants

Sulak, M. A., Fong, L., Mika, K. M., Chigurupati, S., Yon, L., Mongan, N. P., Emes, R. D., & Lynch, V. J. (2016) · eLife · doi:10.7554/elife.11994 · Cited by 342 · see citing works

A Designed Inhibitor of p53 Aggregation Rescues p53 Tumor Suppression in Ovarian Carcinomas

Soragni, A., Janzen, D. M., Johnson, L. M., Lindgren, A. G., Thai-Quynh Nguyen, A., Tiourin, E., Soriaga, A. B., Lu, J., Jiang, L., Faull, K. F., et al. (2016) · Cancer Cell · doi:10.1016/j.ccell.2015.12.002 · Cited by 341 · see citing works

Phase II Study of WEE1 Inhibitor AZD1775 Plus Carboplatin in Patients With TP53-Mutated Ovarian Cancer Refractory or Resistant to First-Line Therapy Within 3 Months

Leijen, S., van Geel, R. M. J. M., Sonke, G. S., de Jong, D., Rosenberg, E. H., Marchetti, S., Pluim, D., van Werkhoven, E. D., Rose, S., Lee, M. A., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.67.5942 · Cited by 341 · see citing works

Bone Marrow Failure in Fanconi Anemia Is Triggered by an Exacerbated p53/p21 DNA Damage Response that Impairs Hematopoietic Stem and Progenitor Cells

Ceccaldi, R., Parmar, K., Mouly, E., Delord, M., Kim, J. M., Regairaz, M., Pla, M., Vasquez, N., Zhang, Q., Pondarré, C., et al. (2012) · Cell stem cell · doi:10.1016/j.stem.2012.05.013 · Cited by 340 · see citing works

Targeting Oncogenic Mutant p53 for Cancer Therapy

Parrales, A., & Iwakuma, T. (2015) · Frontiers in Oncology · doi:10.3389/fonc.2015.00288 · Cited by 335 · see citing works

Chromosome stability, in the absence of apoptosis, is critical for suppression of tumorigenesis in Trp53 mutant mice

Liu, G., Parant, J. M., Lang, G., Chau, P., Chavez-Reyes, A., El-Naggar, A. K., Multani, A., Chang, S., & Lozano, G. (2004) · Nature Genetics · doi:10.1038/ng1282 · Cited by 325 · see citing works

Allele-Specific p53 Mutant Reactivation

Yu, X., Vázquez, A., Levine, A. J., & Carpizo, D. R. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.03.042 · Cited by 320 · see citing works

Clinical Overview of MDM2/X-Targeted Therapies

Burgess, A., Chia, K. M., Haupt, S., Thomas, D., Haupt, Y., & Lim, E. (2016) · Frontiers in Oncology · doi:10.3389/fonc.2016.00007 · Cited by 315 · see citing works

The Origins and Evolution of the p53 Family of GenesPreprint

Белый, В. А., Ak, P., Markert, E. K., Wang, H., Hu, W., Puzio‐Kuter, A. M., & Levine, A. J. (2009) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a001198 · Cited by 293 · see citing works

A panel of isogenic human cancer cells suggests a therapeutic approach for cancers with inactivated p53

Sur, S., Pagliarini, R. A., Bunz, F., Rago, C., Diaz, L. A., Kinzler, K. W., Vogelstein, B., & Papadopoulos, N. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0813333106 · Cited by 293 · see citing works

p53 Efficiently Suppresses Tumor Development in the Complete Absence of Its Cell-Cycle Inhibitory and Proapoptotic Effectors p21, Puma, and Noxa

Valente, L. J., Gray, D. H. D., Michalak, E. M., Hofbauer, J. P., Egle, A., Scott, C. L., Janic, A., & Strasser, A. (2013) · Cell Reports · doi:10.1016/j.celrep.2013.04.012 · Cited by 292 · see citing works

Abrogation of oncogene-associated apoptosis allows transformation of p53-deficient cells.

Lowe, S. W., Jacks, T., Housman, D. E., & Ruley, H. E. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.6.2026 · Cited by 286 · see citing works

A positive feedback loop between the p53 and Lats2 tumor suppressors prevents tetraploidizationPreprint

Aylon, Y., Michael, D., Shmueli, A., Yabuta, N., Nojima, H., & Oren, M. (2006) · Genes & Development · doi:10.1101/gad.1447006 · Cited by 284 · see citing works

Deletions linked to TP53 loss drive cancer through p53-independent mechanisms

Liu, Y., Chen, C., Xu, Z., Scuoppo, C., Rillahan, C. D., Gao, J., Spitzer, B. G., Bosbach, B., Kastenhuber, E. R., Baslan, T., et al. (2016) · Nature · doi:10.1038/nature17157 · Cited by 272 · see citing works

A peptide that binds and stabilizes p53 core domain: Chaperone strategy for rescue of oncogenic mutants

Friedler, A., Hansson, L. O., Veprintsev, D. B., Freund, S. M. V., Rippin, T. M., Nikolova, P. V., Proctor, M. R., Rüdiger, S., & Fersht, A. R. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.241629998 · Cited by 268 · see citing works

p53 cooperates with DNA methylation and a suicidal interferon response to maintain epigenetic silencing of repeats and noncoding RNAs

Leonova, K. I., Brodsky, L., Lipchick, B. C., Pal, M., Novototskaya, L. R., Chenchik, A. A., Sen, G. C., Komarova, E. A., & Gudkov, A. V. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1216922110 · Cited by 261 · see citing works

p53 Functions through Stress- and Promoter-Specific Recruitment of Transcription Initiation Components before and after DNA Damage

Espinosa, J. M., Verdun, R. E., & Emerson, B. M. (2003) · Molecular Cell · doi:10.1016/s1097-2765(03)00359-9 · Cited by 256 · see citing works

Epithelial-Mesenchymal Transition Induced by Senescent Fibroblasts

Laberge, R.-M., Awad, P., Campisi, J., & Desprez, P.-Y. (2012) · Cancer Microenvironment · doi:10.1007/s12307-011-0069-4 · Cited by 255 · see citing works

TP53 loss creates therapeutic vulnerability in colorectal cancer

Liu, Y., Zhang, X., Han, C., Wan, G., Huang, X., Ivan, C., Jiang, D., Rodriguez‐Aguayo, C., Lopez‐Berestein, G., Rao, P. H., et al. (2015) · Nature · doi:10.1038/nature14418 · Cited by 240 · see citing works

Global analysis of p53-regulated transcription identifies its direct targets and unexpected regulatory mechanisms

Allen, M. A., Andrysík, Z., Dengler, V. L., Mellert, H. S., Guarnieri, A. L., Freeman, J. A., Sullivan, K. D., Galbraith, M. D., Luo, X., Kraus, W. L., et al. (2014) · eLife · doi:10.7554/elife.02200 · Cited by 238 · see citing works

p53-Dependent Nestin Regulation Links Tumor Suppression to Cellular Plasticity in Liver Cancer

Tschaharganeh, D. F., Xue, W., Calvisi, D. F., Evert, M., Michurina, T. V., Dow, L. E., Banito, A., Katz, S. F., Kastenhuber, E. R., Weissmueller, S., et al. (2014) · Cell · doi:10.1016/j.cell.2014.05.051 · Cited by 227 · see citing works

Targeting Chk1 in p53-deficient triple-negative breast cancer is therapeutically beneficial in human-in-mouse tumor models

Ma, C. X., Cai, S., Li, S., Ryan, C. E., Guo, Z., Schaiff, W. T., Li, L., Hoog, J., Goiffon, R., Prat, A., et al. (2012) · Journal of Clinical Investigation · doi:10.1172/jci58765 · Cited by 224 · see citing works

p53 genes function to restrain mobile elementsPreprint

Wylie, A., Jones, A. E., D’Brot, A., Lu, W.-J., Kurtz, P., Moran, J. V., Rakheja, D., Chen, K. S.-M., Hammer, R. E., Comerford, S. A., et al. (2015) · Genes & Development · doi:10.1101/gad.266098.115 · Cited by 198 · see citing works

Depletion of a Putatively Druggable Class of Phosphatidylinositol Kinases Inhibits Growth of p53-Null Tumors

Emerling, B. M., Hurov, J., Poulogiannis, G., Tsukazawa, K. S., Choo-Wing, R., Wulf, G. M., Bell, E. L., Shim, H., Lamia, K. A., Rameh, L. E., et al. (2013) · Cell · doi:10.1016/j.cell.2013.09.057 · Cited by 195 · see citing works

Regulation of AIF expression by p53

Stambolsky, P., Weisz, L., Shats, I., Klein, Y., Goldfinger, N., Oren, M., & Rotter, V (2006) · Cell Death &amp; Differentiation · doi:10.1038/sj.cdd.4401965 · Cited by 194 · see citing works

Mutant p53 enhances MET trafficking and signalling to drive cell scattering and invasion

Muller, P. A. J., Trinidad, A. G., Timpson, P., Morton, J. P., Zanivan, S. R., van den Berghe, P. V. E., Nixon, C., Karim, S. A., Caswell, P. T., Noll, J. E., et al. (2012) · Oncogene · doi:10.1038/onc.2012.148 · Cited by 192 · see citing works

Activation of a promyelocytic leukemia–tumor protein 53 axis underlies acute promyelocytic leukemia cure

Ablain, J., Rice, K. L., Soilihi, H., de Reyniès, A., Minucci, S., & de Thé, H. (2014) · Nature Medicine · doi:10.1038/nm.3441 · Cited by 190 · see citing works

A planarian p53 homolog regulates proliferation and self-renewal in adult stem cell lineages

Pearson, B. J., & Alvarado, A. S. (2010) · Development · doi:10.1242/dev.044297 · Cited by 188 · see citing works

Mad2 Is a Critical Mediator of the Chromosome Instability Observed upon Rb and p53 Pathway Inhibition

Schvartzman, J.-M., Duijf, P. H. G., Sotillo, R., Coker, C., & Benezra, R. (2011) · Cancer Cell · doi:10.1016/j.ccr.2011.04.017 · Cited by 181 · see citing works

Suppression of tumorigenesis by the p53 target PUMA

Hemann, M. T., Zilfou, J. T., Zhao, Z., Burgess, D. J., Hannon, G. J., & Lowe, S. W. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0403286101 · Cited by 180 · see citing works

Synthesis of single-crystal-like nanoporous carbon membranes and their application in overall water splitting

Wang, H., Min, S., Ma, C., Liu, Z., Zhang, W., Wang, Q., Li, D., Li, Y., Turner, S., Han, Y., et al. (2017) · Nature Communications · doi:10.1038/ncomms13592 · Cited by 176 · see citing works

p53 loss promotes acute myeloid leukemia by enabling aberrant self-renewalPreprint

Zhao, Z., Zuber, J. A., Díaz-Flores, E., Lintault, L., Kogan, S. C., Shannon, K., & Lowe, S. W. (2010) · Genes & Development · doi:10.1101/gad.1940710 · Cited by 167 · see citing works

A telomere-dependent DNA damage checkpoint induced by prolonged mitotic arrest

Hayashi, M., Cesare, A. J., Fitzpatrick, J. A. J., Denchi, E. L., & Karlseder, J. (2012) · Nature Structural & Molecular Biology · doi:10.1038/nsmb.2245 · Cited by 166 · see citing works

The p53 Family Coordinates Wnt and Nodal Inputs in Mesendodermal Differentiation of Embryonic Stem Cells

Wang, Q., Zou, Y., Nowotschin, S., Kim, S. Y., Li, Q. V., Soh, C.-L., Su, J., Zhang, C., Shu, W., Xi, Q., et al. (2016) · Cell stem cell · doi:10.1016/j.stem.2016.10.002 · Cited by 163 · see citing works

p53 Prohibits Propagation of Chromosome Segregation Errors that Produce Structural Aneuploidies

Soto, M., Raaijmakers, J. A., Bakker, B., Spierings, D. C. J., Lansdorp, P. M., Foijer, F., & Medema, R. H. (2017) · Cell Reports · doi:10.1016/j.celrep.2017.05.055 · Cited by 162 · see citing works

Genome Stability Requires p53

Eischen, C. M. (2016) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a026096 · Cited by 161 · see citing works

Caught in the cross fire: p53 in inflammation

Cooks, T., Harris, C. C., & Oren, M. (2014) · Carcinogenesis · doi:10.1093/carcin/bgu134 · Cited by 160 · see citing works

Inactivation of p53 in breast cancers correlates with stem cell transcriptional signatures

Mizuno, H., Spike, B. T., Wahl, G. M., & Levine, A. J. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1017001108 · Cited by 159 · see citing works

Clinicopathological and prognostic significance of programmed cell death ligand-1 expression in lung adenocarcinoma and its relationship with p53 status

Cha, Y. J., Kim, H. R., Lee, C. Y., Cho, B. C., & Shim, H. S. (2016) · Lung Cancer · doi:10.1016/j.lungcan.2016.05.001 · Cited by 157 · see citing works

Multipolar mitosis of tetraploid cells: inhibition by p53 and dependency on Mos

Vitale, I., Senovilla, L., Jemaà, M., Michaud, M., Galluzzi, L., Kepp, O., Nanty, L., Criollo, A., Rello‐Varona, S., Manic, G., et al. (2010) · The EMBO Journal · doi:10.1038/emboj.2010.11 · Cited by 146 · see citing works

Selection against PUMA Gene Expression in Myc-Driven B-Cell Lymphomagenesis

Garrison, S. P., Jeffers, J. R., Yang, C., Nilsson, J. A., Hall, M. A., Rehg, J. E., Yue, W., Yu, J., Zhang, L., Onciu, M. M., et al. (2008) · Molecular and Cellular Biology · doi:10.1128/mcb.00907-07 · Cited by 145 · see citing works

Mutant p53 cooperates with the SWI/SNF chromatin remodeling complex to regulate VEGFR2 in breast cancer cellsPreprint

Pfister, N. T., Fomin, V., Regunath, K., Zhou, J. Y., Zhou, W., Silwal‐Pandit, L., Freed-Pastor, W. A., Laptenko, O., Neo, S. P., Bargonetti, J., et al. (2015) · Genes & Development · doi:10.1101/gad.263202.115 · Cited by 143 · see citing works

The Human <i>TLR</i> Innate Immune Gene Family Is Differentially Influenced by DNA Stress and <i>p53</i> Status in Cancer Cells

Shatz, M., Menendez, D., & Resnick, M. A. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-4134 · Cited by 143 · see citing works

Restoring expression of wild-type p53 suppresses tumor growth but does not cause tumor regression in mice with a p53 missense mutation

Wang, Y., Suh, Y., Fuller, M. Y., Jackson, J. G., Xiong, S., Terzian, T., Quintás‐Cardama, A., Bankson, J. A., El‐Naggar, A. K., & Lozano, G. (2011) · Journal of Clinical Investigation · doi:10.1172/jci44504 · Cited by 132 · see citing works

IAPP-driven metabolic reprogramming induces regression of p53-deficient tumours in vivo

Venkatanarayan, A., Raulji, P., Norton, W., Chakravarti, D., Coarfa, C., Su, X., Sandur, S. K., Ramirez, M. S., Lee, J., Kingsley, C. V., et al. (2014) · Nature · doi:10.1038/nature13910 · Cited by 131 · see citing works

Increased Oxidative Metabolism in the Li–Fraumeni Syndrome

Wang, P., Ma, W., Park, J., Celi, F. S., Arena, R. A., Choi, J. W., Ali, Q. A., Tripodi, D., Zhuang, J., Lago, C. U., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1214091 · Cited by 126 · see citing works

Centrosomes, chromosome instability (CIN) and aneuploidy

Vitre, B., & Cleveland, D. W. (2012) · Current Opinion in Cell Biology · doi:10.1016/j.ceb.2012.10.006 · Cited by 123 · see citing works

p53 as a target for cancer vaccines: recombinant canarypox virus vectors expressing p53 protect mice against lethal tumor cell challenge.

Roth, J., Dittmer, D. P., Réa, D., Tartaglia, J., Paoletti, E., & Levine, A. J. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.10.4781 · Cited by 118 · see citing works

Autophagy Controls the Kinetics and Extent of Mitochondrial Apoptosis by Regulating PUMA Levels

Thorburn, J., Andrysík, Z., Staskiewicz, L., Gump, J. M., Maycotte, P., Oberst, A., Green, D. R., Espinosa, J. M., & Thorburn, A. M. (2014) · Cell Reports · doi:10.1016/j.celrep.2014.02.036 · Cited by 118 · see citing works

Metastatic melanoma patients treated with dendritic cell vaccination, Interleukin-2 and metronomic cyclophosphamide: results from a phase II trial

Ellebæk, E., Engell-Noerregaard, L., Iversen, T. Z., Frøsig, T. M., Ahmad, S. M., Hadrup, S. R., Andersen, M. H., & Svane, I. M. (2012) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-012-1242-4 · Cited by 118 · see citing works

Pathologies Associated with the p53 ResponsePreprint

Gudkov, A. V., & Komarova, E. A. (2010) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a001180 · Cited by 116 · see citing works

Regulation of p53 is critical for vertebrate limb regeneration

Yun, M. H., Gates, P. B., & Brockes, J. P. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1310519110 · Cited by 112 · see citing works

p53 on the crossroad between regeneration and cancer

Charni‐Natan, M., Aloni-Grinstein, R., Molchadsky, A., & Rotter, V. (2016) · Cell Death and Differentiation · doi:10.1038/cdd.2016.117 · Cited by 112 · see citing works

p53 dynamics in response to DNA damage vary across cell lines and are shaped by efficiency of DNA repair and activity of the kinase ATM

Stewart-Ornstein, J., & Lahav, G. (2017) · Science Signaling · doi:10.1126/scisignal.aah6671 · Cited by 112 · see citing works

p53 regulates glucose metabolism by miR-34a

Kim, H.-R., Roe, J., Lee, J., Cho, E., & Youn, H. (2013) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2013.06.043 · Cited by 109 · see citing works

Tumor Suppressor p53 Alters Host Cell Metabolism to Limit Chlamydia trachomatis Infection

Siegl, C., Prusty, B. K., Rajeeve, K., Wischhusen, J., & Rudel, T. (2014) · Cell Reports · doi:10.1016/j.celrep.2014.10.004 · Cited by 109 · see citing works

Suppression of Host p53 Is Critical for Plasmodium Liver-Stage Infection

Kaushansky, A., Ye, A. S., Austin, L. S., Mikolajczak, S. A., Vaughan, A. M., Camargo, N. M., Metzger, P. G., Douglass, A. N., MacBeath, G., & Kappe, S. H. I. (2013) · Cell Reports · doi:10.1016/j.celrep.2013.02.010 · Cited by 105 · see citing works

The Inherited p53 Mutation in the Brazilian PopulationPreprint

Achatz, M. I., & Zambetti, G. P. (2016) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a026195 · Cited by 99 · see citing works

p53 in neurodegenerative diseases and brain cancers

Checler, F., & da Costa, C. A. (2013) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2013.11.009 · Cited by 97 · see citing works

Divergent Evolution of Human p53 Binding Sites: Cell Cycle Versus Apoptosis

Horvath, M. M., Wang, X., Resnick, M. A., & Bell, D. A. (2007) · PLoS Genetics · doi:10.1371/journal.pgen.0030127 · Cited by 94 · see citing works

The p53 circuit board

Sullivan, K. D., Gallant‐Behm, C. L., Henry, R. E., Fraikin, J.-L., & Espinosa, J. M. (2012) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2012.01.004 · Cited by 92 · see citing works

Gene-specific repression of the p53 target gene PUMA via intragenic CTCF–Cohesin bindingPreprint

Gomes, N. P., & Espinosa, J. M. (2010) · Genes & Development · doi:10.1101/gad.1881010 · Cited by 92 · see citing works

p53Ψ is a transcriptionally inactive p53 isoform able to reprogram cells toward a metastatic-like state

Şentürk, Ş., Yao, Z., Camiolo, M. J., Stiles, B. M., Rathod, T., Walsh, A. M., Nemajerová, A., Lazzara, M. J., Altorki, N. K., Krainer, A. R., et al. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1321640111 · Cited by 90 · see citing works

Induction of p53-specific immune responses in colorectal cancer patients receiving a recombinant ALVAC-p53 candidate vaccine.

van der Burg, S. H., Menon, A. G., Redeker, A., Bonnet, M.-C., Drijfhout, J. W., Tollenaar, R. A. �. �., van de Velde, C. J. �., Moingeon, P. E., Kuppen, P. J. K., Offringa, R., et al. (2002) · PubMed · Cited by 90 · see citing works

Regulation of the p53 transcriptional response by structurally diverse core promoters

Morachis, J. M., Murawsky, C. M., & Emerson, B. M. (2010) · Genes &amp; Development · doi:10.1101/gad.1856710 · Cited by 86 · see citing works

Regulation of female reproduction by p53 and its family members

Feng, Z., Zhang, C., Kang, H., et al. (2011) · The FASEB Journal · doi:10.1096/fj.10-180166 · Cited by 86 · see citing works

Full p53 transcriptional activation potential is dispensable for tumor suppression in diverse lineages

Jiang, D., Brady, C. A., Johnson, T. M., Lee, E. Y., Park, E. J., Scott, M. P., & Attardi, L. D. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1111245108 · Cited by 86 · see citing works

p53: Guardian of reprogramming

Ménendez, S., Camus, S., & Belmonte, J. C. I. (2010) · Cell Cycle · doi:10.4161/cc.9.19.13301 · Cited by 84 · see citing works

An open-label phase I dose-finding study of APR-246 in hematological malignancies

Deneberg, S., Cherif, H., Lazarevic, V, Andersson, P.-O., von Euler, M., Juliusson, G., & Lehmann, S. (2016) · Blood Cancer Journal · doi:10.1038/bcj.2016.60 · Cited by 84 · see citing works

Reactivating mutant p53 using small molecules as zinc metallochaperones: awakening a sleeping giant in cancer

Blanden, A. R., Yu, X., Loh, S. N., Levine, A. J., & Carpizo, D. R. (2015) · Drug Discovery Today · doi:10.1016/j.drudis.2015.07.006 · Cited by 83 · see citing works

The absence of p53 is critical for the induction of apoptosis by 5-aza-2′-deoxycytidine

Nieto, M. D., Samper, E., Fraga, M. F., de Buitrago, G. G., Esteller, M., & Serrano, M. (2004) · Oncogene · doi:10.1038/sj.onc.1207175 · Cited by 83 · see citing works

Mdm2 and p53 are highly conserved from placozoans to man

Lane, D. P., Cheok, C. F., Brown, C. J., Madhumalar, A., Ghadessy, F. J., & Verma, C. S. (2010) · Cell Cycle · doi:10.4161/cc.9.3.10516 · Cited by 79 · see citing works

The Paradox of p53: What, How, and Why?Preprint

Aylon, Y., & Oren, M. (2016) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a026328 · Cited by 79 · see citing works

TP53 exon-6 truncating mutations produce separation of function isoforms with pro-tumorigenic functions

Shirole, N. H., Pal, D., Kastenhuber, E. R., Şentürk, Ş., Boroda, J. U., Pisterzi, P., Miller, M. A., Munoz, G., Anderluh, M., Ladanyi, M., et al. (2016) · eLife · doi:10.7554/elife.17929 · Cited by 79 · see citing works

Heterogeneity of Li-Fraumeni Syndrome links to unequal gain-of-function effects of p53 mutations

Xu, J., Qian, J., Hu, Y., Wang, J., Zhou, X., Chen, H., & Fang, J. (2014) · Scientific Reports · doi:10.1038/srep04223 · Cited by 76 · see citing works

Enzymatic Kinetic Resolution of 2-Piperidineethanol for the Enantioselective Targeted and Diversity Oriented Synthesis

Perdicchia, D., Christodoulou, M. S., Fumagalli, G., et al. (2015) · International Journal of Molecular Sciences · doi:10.3390/ijms17010017 · Cited by 76 · see citing works

Safeguards for Cell Cooperation in Mouse Embryogenesis Shown by Genome-Wide Cheater Screen

Déjosez, M., Ura, H., Brandt, V. L., & Zwaka, T. P. (2013) · Science · doi:10.1126/science.1241628 · Cited by 75 · see citing works

p53 Maintains Baseline Expression of Multiple Tumor Suppressor Genes

Pappas, K., Xu, J., Zairis, S., Resnick‐Silverman, L., Abate, F., Steinbach, N., Ozturk, S., Saal, L. H., Su, T., Cheung, P., et al. (2017) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-17-0089 · Cited by 75 · see citing works

Novel targets and interaction partners of mutant p53 Gain-Of-Function

Aschauer, L., & Muller, P. A. J. (2016) · Biochemical Society Transactions · doi:10.1042/bst20150261 · Cited by 72 · see citing works

P53 and the defenses against genome instability caused by transposons and repetitive elements

Levine, A. J., Ting, D. T., & Greenbaum, B. D. (2016) · BioEssays · doi:10.1002/bies.201600031 · Cited by 72 · see citing works

The Numb/p53 circuitry couples replicative self-renewal and tumor suppression in mammary epithelial cells

Tosoni, D., Zecchini, S., Coazzoli, M., Colaluca, I. N., Mazzarol, G., Rubio, A., Caccia, M., Villa, C. E., Zilian, O., Fiore, P. P. D., et al. (2015) · The Journal of Cell Biology · doi:10.1083/jcb.201505037 · Cited by 67 · see citing works

Emerging Non-Canonical Functions and Regulation by p53: p53 and Stemness

Olivos, D. J., & Mayo, L. D. (2016) · International Journal of Molecular Sciences · doi:10.3390/ijms17121982 · Cited by 65 · see citing works

p53 is essential for DNA methylation homeostasis in naïve embryonic stem cells, and its loss promotes clonal heterogeneityPreprint

Tovy, A., Spiro, A., McCarthy, R. L., Shipony, Z., Aylon, Y., Allton, K. L., Ainbinder, E., Furth, N., Tanay, A., Barton, M. C., et al. (2017) · Genes & Development · doi:10.1101/gad.299198.117 · Cited by 64 · see citing works

p53 integrates host defense and cell fate during bacterial pneumonia

Madenspacher, J. H., Azzam, K. M., Gowdy, K. M., Malcolm, K. C., Nick, J. A., Dixon, D., Aloor, J. J., Draper, D. W., Guardiola, J. J., Shatz, M., et al. (2013) · The Journal of Experimental Medicine · doi:10.1084/jem.20121674 · Cited by 63 · see citing works

Cancer‐specific mutations in p53 induce the translation of Δ160p53 promoting tumorigenesis

Candeias, M. M., Hagiwara, M., & Matsuda, M. (2016) · EMBO Reports · doi:10.15252/embr.201541956 · Cited by 62 · see citing works

Addition of interferon‐α to the p53‐SLP® vaccine results in increased production of interferon‐γ in vaccinated colorectal cancer patients: A phase I/II clinical trial

Zeestraten, E. C. M., Speetjens, F. M., Welters, M. J. P., Saadatmand, S., Stynenbosch, L. F. M., Jongen, R., Kapiteijn, E., Gelderblom, H. A. J., Nijman, H. W., Valentijn, A. R. P. M., et al. (2012) · International Journal of Cancer · doi:10.1002/ijc.27819 · Cited by 61 · see citing works

Reactivation of p53 mutants by p53 reactivation and induction of massive apoptosis in thyroid cancer cells

Messina, R. L., Sanfilippo, M., Vella, V., Pandini, G., Vigneri, P. G., Nicolosi, M. L., Gianì, F., Vigneri, R., & Frasca, F. (2011) · International Journal of Cancer · doi:10.1002/ijc.26228 · Cited by 57 · see citing works

p53 activity is selectively licensed in the Drosophila stem cell compartment

Wylie, A., Lu, W.-J., D’Brot, A., Buszczak, M., & Abrams, J. (2014) · eLife · doi:10.7554/elife.01530 · Cited by 57 · see citing works

Misfolding, Aggregation, and Disordered Segments in c-Abl and p53 in Human Cancer

de Oliveira, G. A. P., Rangel, L. P., da Costa, D. C. F., & Silva, J. L. (2015) · Frontiers in Oncology · doi:10.3389/fonc.2015.00097 · Cited by 55 · see citing works

p53 family in development

Danilova, N., Sakamoto, K. M., & Lin, S. (2008) · Mechanisms of Development · doi:10.1016/j.mod.2008.09.003 · Cited by 55 · see citing works

Interactions of Chromatin Context, Binding Site Sequence Content, and Sequence Evolution in Stress-Induced p53 Occupancy and Transactivation

Su, D., Wang, X., Campbell, M. R., Song, L., Safi, A., Crawford, G. E., & Bell, D. A. (2015) · PLoS Genetics · doi:10.1371/journal.pgen.1004885 · Cited by 54 · see citing works

Exploiting the p53 Pathway for TherapyPreprint

Cheok, C. F., & Lane, D. P. (2017) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a026310 · Cited by 51 · see citing works

The scaffold protein Nde1 safeguards the brain genome during S phase of early neural progenitor differentiation

Houlihan, S. L., & Feng, Y. (2014) · eLife · doi:10.7554/elife.03297 · Cited by 49 · see citing works

Aberrant Expression and Mutation-Inducing Activity of AID in Human Lung Cancer

Shinmura, K., Igarashi, H., Goto, M., Tao, H., Yamada, H., Matsuura, S., Tajima, M., Matsuda, T., Yamane, A., Funai, K., et al. (2011) · Annals of Surgical Oncology · doi:10.1245/s10434-011-1568-8 · Cited by 46 · see citing works

p53-regulated autophagy is controlled by glycolysis and determines cell fate

Duan, L., Perez, R. E., Davaadelger, B., Dedkova, E. N., Blatter, L. A., & Maki, C. G. (2015) · Oncotarget · doi:10.18632/oncotarget.5218 · Cited by 45 · see citing works

Exploiting Synthetic Lethal Interactions Between DNA Damage Signaling, Checkpoint Control, and p53 for Targeted Cancer Therapy

Morandell, S., & Yaffe, M. B. (2012) · Progress in molecular biology and translational science · doi:10.1016/b978-0-12-387665-2.00011-0 · Cited by 44 · see citing works

p53 regulation upon genotoxic stress: intricacies and complexities

Kumari, R., Kohli, S., & Das, S. (2014) · Molecular & Cellular Oncology · doi:10.4161/23723548.2014.969653 · Cited by 41 · see citing works

The Cytidine Deaminase APOBEC3 Family Is Subject to Transcriptional Regulation by p53

Menéndez, D., Nguyen, T., Snipe, J. R., & Resnick, M. A. (2017) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-17-0019 · Cited by 40 · see citing works

ATM regulates cell fate choice upon p53 activation by modulating mitochondrial turnover and ROS levels

Sullivan, K. D., Palaniappan, V. V., & Espinosa, J. M. (2014) · Cell Cycle · doi:10.4161/15384101.2014.973330 · Cited by 39 · see citing works

The cooperating mutation or “second hit” determines the immunologic visibility toward MYC-induced murine lymphomas

Schuster, C., Berger, A., Hoelzl, M. A., Putz, E. M., Frenzel, A., Simma, O., Moritz, N., Hoelbl‐Kovacic, A., Kovačic, B., Freissmuth, M., et al. (2011) · Blood · doi:10.1182/blood-2010-10-313098 · Cited by 38 · see citing works

Conservation of all three p53 family members and Mdm2 and Mdm4 in the cartilaginous fish

Lane, D. P., Madhumalar, A., Lee, A., Tay, B.-H., Verma, C. S., Brenner, S., & Venkatesh, B. (2011) · Cell Cycle · doi:10.4161/cc.10.24.18567 · Cited by 31 · see citing works

Histone modifications and p53 binding poise the p21 promoter for activation in human embryonic stem cells

Itahana, Y., Zhang, J., Göke, J., Vardy, L. A., Han, R., Iwamoto, K., Cukuroglu, E., Robson, P., Pouladi, M. A., Colman, A., et al. (2016) · Scientific Reports · doi:10.1038/srep28112 · Cited by 30 · see citing works

The Mdm2 and p53 genes are conserved in the Arachnids

Lane, D. P., Cheok, C. F., Brown, C. J., et al. (2010) · Cell Cycle · doi:10.4161/cc.9.4.10616 · Cited by 28 · see citing works

The p53 inducing drug dosage may determine quiescence or senescence

Lane, D. P., Verma, C. S., & Fang, C. C. (2010) · Aging · doi:10.18632/aging.100229 · Cited by 27 · see citing works

The transcriptional activity of HERV-I LTR is negatively regulated by its cis-elements and wild type p53 tumor suppressor protein

Chang, N.-T., Yang, W., Huang, H.-C., Yeh, K., & Wu, C.-W. (2006) · Journal of Biomedical Science · doi:10.1007/s11373-006-9126-2 · Cited by 25 · see citing works

Identification of two p53 isoforms from Litopenaeus vannamei and their interaction with NF-κB to induce distinct immune response

Li, H., Wang, S., Chen, Y., Lǚ, K., Yin, B., Li, S., He, J., & Li, C. (2017) · Scientific Reports · doi:10.1038/srep45821 · Cited by 25 · see citing works

Disparate chromatin landscapes and kinetics of inactivation impact differential regulation of p53 target genes

Gomes, N. P., & Espinosa, J. M. (2010) · Cell Cycle · doi:10.4161/cc.9.17.12998 · Cited by 23 · see citing works

Coordinated Tumor Suppression by Chromosome 8p

Tschaharganeh, D. F., Bosbach, B., & Lowe, S. W. (2016) · Cancer Cell · doi:10.1016/j.ccell.2016.04.011 · Cited by 17 · see citing works

Overcoming immunosuppression to enhance a p53MVA vaccine

Hardwick, N., Chung, V., Cristea, M., Ellenhorn, J. D., & Diamond, D. J. (2014) · OncoImmunology · doi:10.4161/21624011.2014.958949 · Cited by 11 · see citing works

Mechanisms of Cellular Senescence: Cell Cycle Arrest and Senescence Associated Secretory Phenotype

Kumari, R., & Jat, P. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.645593 · Cited by 1,622 · see citing works

Mechanisms and functions of cellular senescence

Herranz, N., & Gil, J. (2018) · Journal of Clinical Investigation · doi:10.1172/jci95148 · Cited by 1,232 · see citing works

Targeting p53 pathways: mechanisms, structures, and advances in therapy

Wang, H., Guo, M., Wei, H., & Chen, Y. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01347-1 · Cited by 1,016 · see citing works

Targeting mutant p53 for efficient cancer therapy

Bykov, V. J. N., Eriksson, S. E., Bianchi, J., & Wiman, K. G. (2018) · Nature Reviews Cancer · doi:10.1038/nrc.2017.109 · Cited by 889 · see citing works

Role of p53 in the Regulation of Cellular Senescence

Mijit, M., Caracciolo, V., Melillo, A., Amicarelli, F., & Giordano, A. (2020) · Biomolecules · doi:10.3390/biom10030420 · Cited by 639 · see citing works

Implications of TP53 allelic state for genome stability, clinical presentation and outcomes in myelodysplastic syndromes

Bernard, E., Nannya, Y., Hasserjian, R. P., Devlin, S. M., Tuechler, H., Medina-Martinez, J. S., Yoshizato, T., Shiozawa, Y., Saiki, R., Malcovati, L., et al. (2020) · Nature Medicine · doi:10.1038/s41591-020-1008-z · Cited by 648 · see citing works

p53 in ferroptosis regulation: The new weapon for the old guardian

Liu, Y., & Gu, W. (2022) · Cell Death &amp; Differentiation · doi:10.1038/s41418-022-00943-y · Cited by 540 · see citing works

The p53 Pathway in Glioblastoma

Zhang, Y., Dube, C., Gibert, M., Cruickshanks, N., Wang, B., Coughlan, M., Yang, Y., Setiady, I., Deveau, C., Saoud, K., et al. (2018) · Cancers · doi:10.3390/cancers10090297 · Cited by 440 · see citing works

Chronic inflammation and the hallmarks of aging

Baechle, J. J., Chen, N., Makhijani, P., Winer, S., Furman, D., & Winer, D. A. (2023) · Molecular Metabolism · doi:10.1016/j.molmet.2023.101755 · Cited by 471 · see citing works

Clonal Hematopoiesis and Evolution to Hematopoietic Malignancies

Bowman, R. L., Busque, L., & Levine, R. L. (2018) · Cell stem cell · doi:10.1016/j.stem.2018.01.011 · Cited by 448 · see citing works

Regulating tumor suppressor genes: post-translational modifications

Chen, L., Liu, S., & Tao, Y. (2020) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-0196-9 · Cited by 449 · see citing works

p53 modifications: exquisite decorations of the powerful guardian

Liu, Y., Tavana, O., & Gu, W. (2019) · Journal of Molecular Cell Biology · doi:10.1093/jmcb/mjz060 · Cited by 392 · see citing works

Transcriptome signature of cellular senescence

Casella, G., Munk, R., Kim, K. M., Piao, Y., De, S., Abdelmohsen, K., & Gorospe, M. (2019) · Nucleic Acids Research · doi:10.1093/nar/gkz555 · Cited by 359 · see citing works

iPLA2β-mediated lipid detoxification controls p53-driven ferroptosis independent of GPX4

Chen, D., Chu, B., Yang, X., Liu, Z., Jin, Y., Kon, N., Rabadan, R., Jiang, X., Stockwell, B. R., & Gu, W. (2021) · Nature Communications · doi:10.1038/s41467-021-23902-6 · Cited by 348 · see citing works

p53, cancer and the immune response

Blagih, J., Buck, M. D., & Vousden, K. H. (2020) · Journal of Cell Science · doi:10.1242/jcs.237453 · Cited by 333 · see citing works

α-Ketoglutarate links p53 to cell fate during tumour suppression

Morris, J. P., Yashinskie, J. J., Koche, R., Chandwani, R., Tian, S., Chen, C.-C., Baslan, T., Marinkovic, Z. S., Sánchez-Rivera, F. J., Leach, S. D., et al. (2019) · Nature · doi:10.1038/s41586-019-1577-5 · Cited by 296 · see citing works

Molecular characterization of mutant <i>TP53</i> acute myeloid leukemia and high-risk myelodysplastic syndrome

Grob, T., Al Hinai, A. S. A., Sanders, M. A., Kavelaars, F. G., Rijken, M., Gradowska, P. L., Biemond, B. J., Breems, D. A., Maertens, J., van Marwijk Kooy, M., et al. (2022) · Blood · doi:10.1182/blood.2021014472 · Cited by 305 · see citing works

Aging of the cells: Insight into cellular senescence and detection Methods.

Mohamad Kamal, N. S., Safuan, S., Shamsuddin, S., & Foroozandeh, P. (2020) · European Journal of Cell Biology · doi:10.1016/j.ejcb.2020.151108 · Cited by 287 · see citing works

CAF hierarchy driven by pancreatic cancer cell p53-status creates a pro-metastatic and chemoresistant environment via perlecan

Vennin, C., Mélénec, P., Rouet, R., Nobis, M., Cazet, A. S., Murphy, K. J., Herrmann, D., Reed, D. A., Lucas, M. C., Warren, S. C., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-10968-6 · Cited by 268 · see citing works

APR-246 reactivates mutant p53 by targeting cysteines 124 and 277

Zhang, Q., Bykov, V. J. N., Wiman, K. G., & Zawacka-Pankau, J. (2018) · Cell Death &amp; Disease · doi:10.1038/s41419-018-0463-7 · Cited by 261 · see citing works

Ordered and deterministic cancer genome evolution after p53 loss

Baslan, T., Morris, J. P., Zhao, Z., Reyes, J., Ho, Y.-J., Tsanov, K. M., Bermeo, J., Tian, S., Zhang, S., Askan, G., et al. (2022) · Nature · doi:10.1038/s41586-022-05082-5 · Cited by 221 · see citing works

Serine, glycine and one‑carbon metabolism in cancer (Review)

Pan, S., Fan, M., Liu, Z., Li, X., & Wang, H. (2020) · International Journal of Oncology · doi:10.3892/ijo.2020.5158 · Cited by 227 · see citing works

Pharmacologic Activation of p53 Triggers Viral Mimicry Response Thereby Abolishing Tumor Immune Evasion and Promoting Antitumor Immunity

Zhou, X., Singh, M., Sanz Santos, G., Guerlavais, V., Carvajal, L. A., Aivado, M., Zhan, Y., Oliveira, M. M. S., Westerberg, L. S., Annis, D. A., et al. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-1741 · Cited by 169 · see citing works

The many faces of p53: something for everyone

Levine, A. J. (2019) · Journal of Molecular Cell Biology · doi:10.1093/jmcb/mjz026 · Cited by 163 · see citing works

IFN-gamma-induced PD-L1 expression in melanoma depends on p53 expression

Thiem, A., Hesbacher, S., Kneitz, H., di Primio, T., Heppt, M. V., Hermanns, H. M., Goebeler, M., Meierjohann, S., Houben, R., & Schrama, D. (2019) · Journal of Experimental &amp; Clinical Cancer Research · doi:10.1186/s13046-019-1403-9 · Cited by 153 · see citing works

Single-cell multi-omics identifies chronic inflammation as a driver of TP53-mutant leukemic evolution

Rodriguez-Meira, A., Norfo, R., Wen, S., Chédeville, A. L., Rahman, H., O’Sullivan, J., Wang, G., Louka, E., Kretzschmar, W. W., Paterson, A., et al. (2023) · Nature Genetics · doi:10.1038/s41588-023-01480-1 · Cited by 158 · see citing works

Cellular senescence in the aging retina and developments of senotherapies for age-related macular degeneration

Lee, K. S., Lin, S., Copland, D. A., Dick, A. D., & Liu, J. (2021) · Journal of Neuroinflammation · doi:10.1186/s12974-021-02088-0 · Cited by 150 · see citing works

Mutations in key driver genes of pancreatic cancer: molecularly targeted therapies and other clinical implications

Hu, H.-F., Ye, Z., Qin, Y., Xu, X.-W., Yu, X.-J., Zhuo, Q.-F., & Ji, S.-R. (2021) · Acta Pharmacologica Sinica · doi:10.1038/s41401-020-00584-2 · Cited by 149 · see citing works

The chemistry of senescence

Lozano-Torres, B., Estepa-Fernández, A., Rovira, M., Orzáez, M., Serrano, M., Martínez-Máñez, R., & Sancenón, F. (2019) · Nature Reviews Chemistry · doi:10.1038/s41570-019-0108-0 · Cited by 140 · see citing works

The Multifaceted Role of Heme in Cancer

Fiorito, V., Chiabrando, D., Petrillo, S., Bertino, F., & Tolosano, E. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2019.01540 · Cited by 129 · see citing works

Genomic context and TP53 allele frequency define clinical outcomes in TP53-mutated myelodysplastic syndromes

Montalban-Bravo, G., Kanagal-Shamanna, R., Benton, C. B., Class, C. A., Chien, K. S., Sasaki, K., Naqvi, K., Alvarado, Y., Kadia, T. M., Ravandi, F., et al. (2020) · Blood Advances · doi:10.1182/bloodadvances.2019001101 · Cited by 133 · see citing works

A P53-Phosphoinositide Signalosome Regulates Nuclear AKT Activation

Chen, M., Choi, S., Wen, T., Chen, C., Thapa, N., Lee, J. H., Cryns, V. L., & Anderson, R. A. (2022) · Nature Cell Biology · doi:10.1038/s41556-022-00949-1 · Cited by 117 · see citing works

<i>TP53</i> copy number and protein expression inform mutation status across risk categories in acute myeloid leukemia

Tashakori, M., Kadia, T., Loghavi, S., Daver, N., Kanagal-Shamanna, R., Pierce, S., Sui, D., Wei, P., Khodakarami, F., Tang, Z., et al. (2022) · Blood · doi:10.1182/blood.2021013983 · Cited by 111 · see citing works

Mutant p53 drives cancer chemotherapy resistance due to loss of function on activating transcription of PUMA

Huang, Y., Liu, N., Liu, J., Liu, Y., Zhang, C., Long, S., Luo, G., Zhang, L., & Zhang, Y. (2019) · Cell Cycle · doi:10.1080/15384101.2019.1688951 · Cited by 94 · see citing works

Identification of cancer sex-disparity in the functional integrity of p53 and its X chromosome network

Haupt, S., Caramia, F., Herschtal, A., Soussi, T., Lozano, G., Chen, H., Liang, H., Speed, T. P., & Haupt, Y. (2019) · Nature Communications · doi:10.1038/s41467-019-13266-3 · Cited by 94 · see citing works

Genetics of familial and sporadic pancreatic cancer

Wood, L. D., Yurgelun, M. B., & Goggins, M. G. (2019) · Gastroenterology · doi:10.1053/j.gastro.2018.12.039 · Cited by 91 · see citing works

Metabolic regulation of somatic stem cells in vivo

Meacham, C. E., DeVilbiss, A. W., & Morrison, S. J. (2022) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-022-00462-1 · Cited by 85 · see citing works

Targeting Therapies for the p53 Protein in Cancer Treatments

Levine, A. J. (2019) · Annual Review of Cancer Biology · doi:10.1146/annurev-cancerbio-030518-055455 · Cited by 84 · see citing works

The mechanistic basis for chromatin regulation by pioneer transcription factors

Iwafuchi‐Doi, M. (2019) · WIREs Systems Biology and Medicine · doi:10.1002/wsbm.1427 · Cited by 82 · see citing works

Inhibition of the glutaredoxin and thioredoxin systems and ribonucleotide reductase by mutant p53-targeting compound APR-246

Haffo, L., Lu, J., Bykov, V. J. N., Martin, S. S., Ren, X., Coppo, L., Wiman, K. G., & Holmgren, A. (2018) · Scientific Reports · doi:10.1038/s41598-018-31048-7 · Cited by 73 · see citing works

p53‐mediated adaptation to serine starvation is retained by a common tumour‐derived mutant

Humpton, T. J., Hock, A. K., Maddocks, O. D. K., & Vousden, K. H. (2018) · Cancer &amp; Metabolism · doi:10.1186/s40170-018-0191-6 · Cited by 58 · see citing works

Insights into regulators of p53 acetylation

Nagasaka, M., Miyajima, C., Aoki, H., Aoyama, M., Morishita, D., Inoue, Y., & Hayashi, H. (2022) · Cells · doi:10.3390/cells11233825 · Cited by 45 · see citing works

PCNA-Mediated Degradation of p21 Coordinates the DNA Damage Response and Cell Cycle Regulation in Individual Cells

Sheng, C., Mendler, I.-H., Rieke, S., Snyder, P., Jentsch, M., Friedrich, D., Drossel, B., & Loewer, A. (2019) · Cell Reports · doi:10.1016/j.celrep.2019.03.031 · Cited by 45 · see citing works

Small-molecule correctors and stabilizers to target p53

Fallatah, M. M. J., Law, F. V., Chow, W. A., & Kaiser, P. (2023) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2023.02.007 · Cited by 44 · see citing works

BOREAS: a global, phase III study of the MDM2 inhibitor navtemadlin (KRT-232) in relapsed/refractory myelofibrosis

Verstovsek, S., Al-Ali, H. K., Mascarenhas, J., Perkins, A., Vannucchi, A. M., Mohan, S. R., Scott, B. L., Woszczyk, D., Koschmieder, S., García-Delgado, R., et al. (2022) · Future Oncology · doi:10.2217/fon-2022-0901 · Cited by 41 · see citing works

MDM2 inhibition in the treatment of glioblastoma: From concept to clinical investigation

Pellot Ortiz, K. I., Rechberger, J. S., Nonnenbroich, L. F., Daniels, D. J., & Sarkaria, J. N. (2023) · Biomedicines · doi:10.3390/biomedicines11071879 · Cited by 30 · see citing works

Translation control by p53.

Kasteri, J., Das, D., Zhong, X., Persaud, L., Francis, A., Muharam, H., & Sauane, M. (2018) · Cancers · doi:10.3390/cancers10050133 · Cited by 24 · see citing works

Natural killer cells limit the clearance of senescent lung adenocarcinoma cells

Stokes, K. L., Cortez-Retamozo, V., Acosta, J., Lauderback, B., Robles-Oteiza, C., Cicchini, M., Pittet, M. J., & Feldser, D. M. (2019) · Oncogenesis · doi:10.1038/s41389-019-0133-3 · Cited by 21 · see citing works

Aging: What We Can Learn From Elephants

Chusyd, D. E., Ackermans, N. L., Austad, S. N., Hof, P. R., Mielke, M. M., Sherwood, C. C., & Allison, D. B. (2021) · Frontiers in Aging · doi:10.3389/fragi.2021.726714 · Cited by 23 · see citing works

Etoposide-induced dna damage is increased in p53 mutants: identification of atr and other genes that influence effects of p53 mutations on top2-induced cytotoxicity

Menendez, D., Anand, J. R., Murphy, C. C., Bell, W. J., Fu, J., Slepushkina, N., Buehler, E., Martin, S. E., Lal-Nag, M., Nitiss, J. L., et al. (2022) · Oncotarget · doi:10.18632/oncotarget.28195 · Cited by 22 · see citing works

TP53 Mutational Status-Based Genomic Signature for Prognosis and Predicting Therapeutic Response in Pancreatic Cancer

Zhang, F., Zhong, W., Li, H., Huang, K., Yu, M., & Liu, Y. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.665265 · Cited by 13 · see citing works

Telomeric 8-Oxoguanine Drives Rapid Premature Senescence In The Absence Of Telomere Shortening

Barnes, R. P., de Rosa, M., Thosar, S. A., Detwiler, A. C., Roginskaya, V., Van Houten, B., Bruchez, M. P., Stewart-Ornstein, J., & Opresko, P. L. (2021) · doi:10.1101/2021.05.05.442662

Delivery versus Potency in Treating Brain Tumors: BI-907828, a MDM2-p53 Antagonist with Limited BBB Penetration but Significant <i>In Vivo</i> Efficacy in Glioblastoma

Zhang, W., Vaubel, R. A., Oh, J.-H., Mladek, A. C., Talele, S., Zhang, W., Waller, K. L., Burgenske, D. M., Sarkaria, J. N., & Elmquist, W. F. (2024) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-23-0217 · Cited by 8 · see citing works

Pharmacokinetic-pharmacodynamic-efficacy modeling of the MDM2 inhibitor brigimadlin in glioblastoma patient-derived xenografts

Vaubel, R. A., Zhang, W., Karbhari, N., Oh, J.-H., Waller, K. L., Mladek, A., Jain, S., Burgenske, D. M., Decker, P. A., Kosel, M. L., et al. (2026) · Neuro-Oncology Advances · doi:10.1093/noajnl/vdaf259

The Interplay between Dysregulated Metabolism and Epigenetics in Cancer

Bassal, M. A. (2023) · Biomolecules · doi:10.3390/biom13060944 · Cited by 19 · see citing works

Epigenetics of early-life lead exposure and effects on brain development

Senut, M.-C., Cingolani, P., Sen, A., Kruger, A., Shaik, A., Hirsch, H., Suhr, S. T., & Ruden, D. (2012) · Epigenomics · doi:10.2217/epi.12.58 · Cited by 151 · see citing works

Epigenetic mechanisms in Alzheimer's disease: Implications for pathogenesis and therapy

Wang, J., Yu, J., Tan, M., Jiang, T., & Tan, L. (2013) · Ageing Research Reviews · doi:10.1016/j.arr.2013.05.003 · Cited by 135 · see citing works

Transgenerational Epigenetic Contributions to Stress Responses: Fact or Fiction?

Nestler, E. J. (2016) · PLoS Biology · doi:10.1371/journal.pbio.1002426 · Cited by 90 · see citing works

The context and potential of epigenetics in oncology

Lopez, J. S., Percharde, M., Coley, H. M., Webb, A., & Crook, T. (2009) · British Journal of Cancer · doi:10.1038/sj.bjc.6604930 · Cited by 105 · see citing works